{
    "clinical_study": {
        "@rank": "6518", 
        "arm_group": {
            "arm_group_label": "Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)", 
            "description": "Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes."
        }, 
        "biospec_descr": {
            "textblock": "saliva"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This clinical trial studies genetic biomarkers from saliva samples in patients with Ewing\n      sarcoma. Studying samples of saliva from patients with cancer in the laboratory may help\n      doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify\n      biomarkers related to cancer."
        }, 
        "brief_title": "Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma", 
        "condition": "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)", 
        "condition_browse": {
            "mesh_term": [
                "Neuroectodermal Tumors", 
                "Neuroectodermal Tumors, Primitive", 
                "Sarcoma, Ewing's", 
                "Neuroectodermal Tumors, Primitive, Peripheral", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the association between the length of Ewing sarcoma breakpoint region\n      1-Friend leukemia virus integration 1 (EWS-FLI1) fusion protein binding sites\n      (microsatellites) and risk of Ewing's sarcoma (ES).\n\n      II. To determine the frequency and commonality of Caucasian ancestral markers in cases of ES\n      self-identified as non-Caucasian (African-American, Asian, Hispanic).\n\n      III. To determine the association between genomic variants in ES-related genes and hernia\n      development (i.e. the integrin signaling pathway) and risk of ES.\n\n      OUTLINE:\n\n      Genomic DNA is extracted from participants' saliva samples and analyzed for expression of\n      EWS-FLI1 and other ES-target genes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is enrolled on ACCRN07\n\n          -  The patient has a diagnosis of Ewing Sarcoma (International Classification of\n             Diseases [ICD] code morphology 9260; topography C40.0-C41.9, C76.0-C76.8, C80.9) and\n             is registered with Children's Oncology Group (COG) by a North American member\n             institution\n\n          -  The patient must be diagnosed with Ewing sarcoma between December 24, 2007 and\n             December 31, 2015\n\n          -  The patient must have at least one biological parent alive and willing to participate\n\n          -  All questionnaire respondents must understand English or Spanish\n\n          -  Concomitant treatment on a therapeutic trial is not required"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with a diagnosis of Ewing Sarcoma meeting other criteria."
            }
        }, 
        "enrollment": {
            "#text": "1650", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876303", 
            "org_study_id": "AEPI10N5", 
            "secondary_id": [
                "NCI-2012-02210", 
                "AEPI10N5", 
                "AEPI10N5", 
                "U10CA098543"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)", 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "email": "joshua.schiffman@hci.utah.edu", 
                "last_name": "Joshua D. Schiffman, MD", 
                "phone": "801-585-5270"
            }, 
            "facility": {
                "address": {
                    "city": "Arcadia", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91006-3776"
                }, 
                "name": "Children's Oncology Group"
            }, 
            "investigator": {
                "last_name": "Joshua D. Schiffman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Genetic Epidemiology of Ewing's Sarcoma", 
        "overall_official": {
            "affiliation": "Children's Oncology Group", 
            "last_name": "Joshua Schiffman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2100", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Risk ratios (RR) for the main effect of gene polymorphisms will be calculated using log-linear models. RRs and 95% confidence intervals for the gene-environment interaction are calculated by stratifying the likelihood according to case exposure.", 
            "measure": "Main effect of gene polymorphisms", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876303"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Children's Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Children's Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Family-Based, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}